Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
about
High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaRapid COJEC versus standard induction therapies for high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaHigh-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastomaReduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastomaPeripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology GroupStriking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era.Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target.Long-term cancer-free survival after infusion of autologous cord blood cells for rejection-unrelated cord blood graft after myeloablative conditioning for t-MDS: a case report.Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionSingle-walled carbon nanotube-mediated small interfering RNA delivery for gastrin-releasing peptide receptor silencing in human neuroblastoma.Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin.Gastrin-releasing peptide receptor silencing suppresses the tumorigenesis and metastatic potential of neuroblastoma.Integrin-linked kinase regulates phosphatase and tensin homologue activity to promote tumorigenesis in neuroblastoma cells.KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With NeuroblastomaPurged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial.Do pharmacokinetic polymorphisms explain treatment failure in high-risk patients with neuroblastoma?Incidence, Survival, and Treatment of Localized and Metastatic Neuroblastoma in Germany 1979-2015.Development and characterization of a human orthotopic neuroblastoma xenograft.Short-Interval Retreatment With Stereotactic Body Radiotherapy (SBRT) for Pediatric Neuroblastoma Resulting in Severe Myositis.Etoposide sensitizes neuroblastoma cells expressing caspase 8 to TRAIL.Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.Feasibility of sequential high-dose chemotherapy in advanced pediatric solid tumors.Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma.Alterations in epithelial and mesenchymal intestinal gene expression during doxorubicin-induced mucositis in mice.KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma.Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials.5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma.Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system.MYCN-amplified stage 2/3 neuroblastoma: excellent survival in the era of anti-GD2 immunotherapy.Results of induction chemotherapy in children older than 18 months with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7).Autologous cord blood transplantation for metastatic neuroblastoma.Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?Treatment and outcome of adult-onset neuroblastoma.Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients.
P2860
Q24186636-5E194E20-6EBD-4801-BE90-277C862AF087Q24187922-5B0A616F-1A6B-4511-8690-7FB984B68B5BQ24200296-F3F60CE0-4432-467F-8AC9-EA24A536A1C0Q24235309-0910848D-35E5-4480-8B00-52BCAB28614FQ33836091-F5C23A73-A752-4E4D-ADAA-71FA9DF2F0B8Q33999779-A3486F1E-B913-4820-AA3F-B03513B10F69Q35077703-9B9ABC2A-927B-40EA-86C5-BCC2754FA618Q35102499-6C514F4F-8B71-411E-94A5-4F382466F578Q35669596-BA874ADC-9B88-4C28-9C09-708D4BC582F9Q36152201-D8762203-B206-46D1-8C62-D36EFCEDA653Q36212437-67C07236-9FDF-4183-A35E-E197B656A157Q36445353-0C7BCC80-9D6A-4B38-B594-4AF86311D27FQ36782374-31C237EF-D3BD-4DF6-A571-F4B9B72411FDQ36861785-E60CD8BD-2DE4-4880-814C-83049CFE9BB4Q36890811-2B50F10E-0009-47C1-BAF4-85D5FEF016F1Q37130228-DA42F378-F6C5-4441-BBBD-9FC77788379BQ37658501-B3B829DE-E306-42E1-BD07-357337500A52Q37834445-0F477A85-346F-4636-94F9-3C31EC8F88FFQ38635452-13C39552-2819-44D5-ADE5-CD90BC446474Q38888609-16CFAA83-DD72-4789-B569-C4BF11F1D9FEQ38916603-01A1E24F-CD81-4B92-835E-5E67932EA54CQ39249745-FB28EBE5-5974-4589-9477-55D15CC90A5CQ39620511-A50AFF8B-E00E-4356-AA55-9C333E461EDAQ40367329-A0B98E13-9955-47E9-81DA-10CEC6E5D72AQ41634067-18A22867-76B4-42A1-BD50-28BF2B0B537FQ41903928-423B17DC-AC25-471C-9736-1C5CB5234899Q41985731-FE0EC4FC-0268-4BB1-9891-F6F54A6DBBAEQ44123857-4C8F6CD1-712C-461D-9E3E-AB1FC901E435Q44260246-74C93A2C-8080-4263-940B-5DED87ECA5E6Q46884985-09711102-66EF-4E17-8F17-B8A04C88C539Q47108370-C148EE1A-B2A6-46F1-9AE2-6916EC09BBE8Q48372855-BAFC38E7-4E2F-48AA-9F79-E19E1F854B18Q49114959-E59BE0FC-35B5-4071-9D45-F5A76D668D27Q50029475-CE17CB51-EDD0-42DD-B6FD-7E5D54ABC881Q52637916-C3875346-BA11-4085-A081-1FDC61004409Q53011367-7D42880B-6301-4B96-8339-F66D3DC8EA58
P2860
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Reduction from seven to five c ...... with high-risk neuroblastoma.
@ast
Reduction from seven to five c ...... with high-risk neuroblastoma.
@en
Reduction from seven to five c ...... with high-risk neuroblastoma.
@nl
type
label
Reduction from seven to five c ...... with high-risk neuroblastoma.
@ast
Reduction from seven to five c ...... with high-risk neuroblastoma.
@en
Reduction from seven to five c ...... with high-risk neuroblastoma.
@nl
prefLabel
Reduction from seven to five c ...... with high-risk neuroblastoma.
@ast
Reduction from seven to five c ...... with high-risk neuroblastoma.
@en
Reduction from seven to five c ...... with high-risk neuroblastoma.
@nl
P2093
P356
P1476
Reduction from seven to five c ...... with high-risk neuroblastoma.
@en
P2093
Brian H Kushner
Kim Kramer
Michael P LaQuaglia
Nai-Kong V Cheung
P304
P356
10.1200/JCO.2004.02.101
P407
P577
2004-12-01T00:00:00Z